Clinical Trials
Finotonlimab Plus SCT200 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lin et alCancer Medicine

A prospective, multicenter, open-label Phase Ib trial evaluated the efficacy and safety of combining finotonlimab (a PD-1 antibody) with SCT200 (an EGFR antibody) in 41 patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study evaluated two patient populations: Cohort A (n = 11), consisting of patients previously treated with platinum-based chemotherapy and immune checkpoint inhibitors, and Cohort B (n = 30), comprising systemic therapy-naïve patients. Dosing consisted of finotonlimab at 200 mg every 3 weeks alongside SCT200 at 6 mg/kg weekly for 12 weeks, followed by 8 mg/kg every 2 weeks. The primary endpoint was objective response rate (ORR).
The combination therapy showed promising activity, particularly in systemic therapy-naïve patients. In Cohort B, the ORR reached 56.7%, with a median progression-free survival (PFS) of 9.6 months and an estimated median overall survival (OS) of 13.6 months. Among previously treated patients in Cohort A, the ORR was 27.3%, with a median PFS of 5.8 months and a median OS of 10.6 months. Treatment-related adverse events were reported as manageable, with the most common being hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%).
Key Takeaways
- In systemic therapy-naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (Cohort B, n = 30), finotonlimab plus SCT200 achieved an objective response rate of 56.7%, a median progression-free survival of 9.6 months, and an estimated median overall survival of 13.6 months.
- In patients previously treated with platinum chemotherapy and immune checkpoint inhibitors (Cohort A, n = 11), the combination yielded an objective response rate of 27.3%, a median progression-free survival of 5.8 months, and a median overall survival of 10.6 months.
- Treatment-related adverse events were manageable, with the most frequent toxicities being hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%).
Read the original sourceCancer Medicine
